Advanced colorectal cancer treatment options beyond standard systemic therapy

Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Eveline Boucher, Marc Peeters, Ben Tran, Heinz-Josef Lenz, Alberto Zaniboni, Howard Hochster, James M Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu, None, Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 372, pp. 1909- 1919 ,(2015) , 10.1056/NEJMOA1414325

Eduardo Arranz, Alan W. Walker, Simon R. Carding, Stella C. Knight, David Bernardo, Lydia Durant, Elizabeth R. Mann, Elizabeth Bassity, Enrique Montalvillo, Ripple Man, Rakesh Vora, Durga Reddi, Fahri Bayiroglu, Luis Fernández-Salazar, Nick R. English, Simon T.C. Peake, Jon Landy, Gui H. Lee, George Malietzis, Yi Harn Siaw, Aravinth U. Murugananthan, Phil Hendy, Eva Sánchez-Recio, Robin K.S. Phillips, Jose A. Garrote, Paul Scott, Julian Parkhill, Malte Paulsen, Ailsa L. Hart, Hafid O. Al-Hassi, Chemokine (C-C Motif) Receptor 2 Mediates Dendritic Cell Recruitment to the Human Colon but Is Not Responsible for Differences Observed in Dendritic Cell Subsets, Phenotype, and Function Between the Proximal and Distal Colon Cellular and molecular gastroenterology and hepatology. ,vol. 2, pp. 22- ,(2016) , 10.1016/J.JCMGH.2015.08.006

Paul Lochhead, Aya Kuchiba, Yu Imamura, Xiaoyun Liao, Mai Yamauchi, Reiko Nishihara, Zhi Rong Qian, Teppei Morikawa, Jeanne Shen, Jeffrey A. Meyerhardt, Charles S. Fuchs, Shuji Ogino, Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication Journal of the National Cancer Institute. ,vol. 105, pp. 1151- 1156 ,(2013) , 10.1093/JNCI/DJT173

Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Takayuki Yoshino, Heinz-Josef Lenz, Richard M Goldberg, Daniel J Sargent, Frank Cihon, Lisa Cupit, Andrea Wagner, Dirk Laurent, None, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial The Lancet. ,vol. 381, pp. 303- 312 ,(2013) , 10.1016/S0140-6736(12)61900-X

Audrey Lasry, Adar Zinger, Yinon Ben-Neriah, Inflammatory networks underlying colorectal cancer. Nature Immunology. ,vol. 17, pp. 230- 240 ,(2016) , 10.1038/NI.3384

Eric Van Cutsem, Andrés Cervantes, Rene Adam, Alberto Sobrero, JH Van Krieken, D Aderka, E Aranda Aguilar, Alberto Bardelli, A Benson, G Bodoky, Fortunato Ciardiello, André D'Hoore, E Diaz-Rubio, J-Y Douillard, M Ducreux, Alfredo Falcone, A Grothey, T Gruenberger, Karin Haustermans, V Heinemann, P Hoff, C-H Köhne, R Labianca, P Laurent-Puig, B Ma, T Maughan, K Muro, N Normanno, P Österlund, WJG Oyen, D Papamichael, G Pentheroudakis, P Pfeiffer, TJ Price, C Punt, J Ricke, A Roth, R Salazar, W Scheithauer, HJ Schmoll, J Tabernero, J Taïeb, Sabine Tejpar, H Wasan, T Yoshino, A Zaanan, D Arnold, None, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Annals of Oncology. ,vol. 27, pp. 1386- 1422 ,(2016) , 10.1093/ANNONC/MDW235

Sabine Tejpar, Sebastian Stintzing, Fortunato Ciardiello, Josep Tabernero, Eric Van Cutsem, Frank Beier, Regina Esser, Heinz-Josef Lenz, Volker Heinemann, Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials JAMA Oncology. ,vol. 3, pp. 194- 201 ,(2017) , 10.1001/JAMAONCOL.2016.3797

Tamas Hickish, Thierry Andre, Lucjan Wyrwicz, Mark Saunders, Tomasz Sarosiek, Judit Kocsis, Radim Nemecek, Wojciech Rogowski, Krzysztof Lesniewski-Kmak, Lubos Petruzelka, Ron N Apte, Prasant Mohanty, Michael Stecher, John Simard, Aimery de Gramont, MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study The Lancet Oncology. ,vol. 18, pp. 192- 201 ,(2017) , 10.1016/S1470-2045(17)30006-2